IL17A and neoplasm: Lipopolysaccharide from Gram-negative bacilli activates the TLR4/MYD88 innate immune signaling pathway leading to an increase in IL23 and IL17, which promotes an inflammatory response and exacerbates tumor progression (27, 30).